SEC Comment Letter 0000000000-23-005296 to SOPHiA GENETICS SA (SOPH)

SOPHiA GENETICS SA
Date: May 18, 2023 · CIK: 0001840706 · Accession: 0000000000-23-005296

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-40627

Date

May 18, 2023

Author

Ross Muken

Form

UPLOAD

Company

SOPHiA GENETICS SA

Letter

United States securities and exchange commission logo May 18, 2023 Ross Muken Chief Financial Officer SOPHiA GENETICS SA 185 Dartmouth Street Floor 5 Boston, MA 02116 Re:SOPHiA GENETICS SA Form 20-F for the Fiscal Year Ended December 31, 2022 Filed March 7, 2023 File No. 001-40627 Dear Ross Muken: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
May 18, 2023
Ross Muken
Chief Financial Officer
SOPHiA GENETICS SA
185 Dartmouth Street Floor 5
Boston, MA 02116
Re:SOPHiA GENETICS SA
Form 20-F for the Fiscal Year Ended December 31, 2022
Filed March 7, 2023
File No. 001-40627
Dear Ross Muken:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io